These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 36726391)

  • 1. MAFLD: a multisystem disease.
    Pipitone RM; Ciccioli C; Infantino G; La Mantia C; Parisi S; Tulone A; Pennisi G; Grimaudo S; Petta S
    Ther Adv Endocrinol Metab; 2023; 14():20420188221145549. PubMed ID: 36726391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAFLD as part of systemic metabolic dysregulation.
    Zhao J; Liu L; Cao YY; Gao X; Targher G; Byrne CD; Sun DQ; Zheng MH
    Hepatol Int; 2024 Apr; ():. PubMed ID: 38594474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.
    Yuan X; Wang X; Wu S; Chen S; Wang Y; Wang J; Lu Y; Sun Y; Fu Q; Wang L
    Hepatobiliary Surg Nutr; 2023 Oct; 12(5):671-681. PubMed ID: 37886198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver.
    Kaya E; Yilmaz Y
    J Clin Transl Hepatol; 2022 Apr; 10(2):329-338. PubMed ID: 35528971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease.
    Kulkarni AV; Sarin SK
    Ther Adv Endocrinol Metab; 2023; 14():20420188231178370. PubMed ID: 37323163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.
    Habibullah M; Jemmieh K; Ouda A; Haider MZ; Malki MI; Elzouki AN
    Front Med (Lausanne); 2024; 11():1291501. PubMed ID: 38323033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.
    Ng CH; Huang DQ; Nguyen MH
    Clin Mol Hepatol; 2022 Oct; 28(4):790-801. PubMed ID: 35545437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of body fat accumulation on metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults.
    Miwa T; Francisque C; Tajirika S; Hanai T; Imamura N; Adachi M; Horita R; Menezes LJ; Kawaguchi T; Shimizu M; Yamamoto M
    Hepatol Res; 2023 Aug; 53(8):691-700. PubMed ID: 37143429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAFLD and CKD: An Updated Narrative Review.
    Mantovani A; Lombardi R; Cattazzo F; Zusi C; Cappelli D; Dalbeni A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
    Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
    J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis.
    Virk GS; Vajje J; Virk NK; Mannam R; Rehman W; Ghobriel NG; Mian IU; Usama M
    Cureus; 2023 Aug; 15(8):e44413. PubMed ID: 37791219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
    Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
    Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
    Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
    Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Clinical Characteristics and Outcomes of MAFLD and NAFLD in Chinese Health Examination Populations.
    Xu X; Zhou X; Tian T; Ding Y; Yu C; Zhao W; Wang X; Lu J; Guo W; Jiang L; Wang Q; Zhang Q; Song C
    J Clin Transl Hepatol; 2023 Aug; 11(4):777-786. PubMed ID: 37408819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
    Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
    World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innate immunity and nonalcoholic fatty liver disease.
    Kountouras J; Kazakos E; Kyrailidi F; Polyzos SA; Zavos C; Arapoglou S; Boziki M; Mouratidou MC; Tzitiridou-Chatzopoulou M; Chatzopoulos D; Doulberis M; Papaefthymiou A; Vardaka E
    Ann Gastroenterol; 2023; 36(3):244-256. PubMed ID: 37144011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.
    Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI
    Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.